Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada

Skowronski, Danuta M.; Li, Yan; Tweed, Sam; Tam, Theresa; Petric, Martin; David, Samara; Marra, Fawziah; Bastien, Nathalie; Lee, Sandra W.; Krajden, Mel; Brunham, Robert C.

doi:10.1503/cmaj.060204

Cited by 55 publications

(76 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly H7 subtypes have been found to have irregular ocular tropisms and in general humans are not considered to be at high infection risk, and Ab responses infrequently detected [15,16]. Hence between different avian strains, there appears to be a gradation of human antibodies for conserved inter-species protein epitopes and further study of other avian strains may confirm this.…”

Section: Discussionmentioning

confidence: 96%

Cross-Reactive Anti-Avian H5N1 Influenza Neutralizing Antibodies in a Normal ‘Exposure-Naive’ Australian Blood Donor Population

Lynch¹,

Selleck²,

Axell³

et al. 2008

TOIJ

View full text Add to dashboard Cite

Abstract:It is necessary to understand whether some humans possess natural humoral-immune protection for avian-H5N1 influenza. To broadly assess an exposure naïve cohort we have examined intravenous immunoglobulins (IVIGs) isolated from pools of many thousands of normal Australian blood donations. In studies of the anti-H5N1 antibody potential of these highly purified IVIG therapeutics and of individual donor sera we have identified antibodies that bind to both H5N1 surface envelope and internal viral proteins and neutralize in vitro MDCK and Vero cell infections by highly pathogenic avian influenza clade I and II and human-derived H5N1 isolates. As this reactivity is removed by adsorption with purified H3N2 and H1N1 strains, anti-H5N1 cross-reacting hetero-typic antibodies are implicated. These findings support that some individuals do contain low levels of specific and neutralizing anti-H5N1 antibodies. The protective relevance of this in vivo remains yet to be determined.

show abstract

Section: Discussionmentioning

confidence: 96%

Cross-Reactive Anti-Avian H5N1 Influenza Neutralizing Antibodies in a Normal ‘Exposure-Naive’ Australian Blood Donor Population

Lynch¹,

Selleck²,

Axell³

et al. 2008

TOIJ

View full text Add to dashboard Cite

show abstract

“…Compliance tends to be suboptimal (8), possibly because of low risk perception among poultry workers (9). Understanding what obstacles prevent workers from wearing complete PPE is needed.…”

Section: Discussionmentioning

confidence: 99%

Personal Protective Equipment and Risk for Avian Influenza (H7N3)

Morgan

Kuhne²,

Nair³

et al. 2009

Emerg. Infect. Dis.

View full text Add to dashboard Cite

An outbreak of avian infl uenza (H7N3) among poultry resulted in laboratory-confi rmed disease in 1 of 103 exposed persons. Incomplete use of personal protective equipment (PPE) was associated with conjunctivitis and infl uenza-like symptoms. Rigorous use of PPE by persons managing avian infl uenza outbreaks may reduce exposure to potentially hazardous infected poultry materials. In April 2006, an outbreak of avian influenza occurred on 3 poultry farms in Norfolk, England (1). Reverse transcription–PCR (RT-PCR) of poultry blood samples and cloacal swabs detected low-pathogenic avian influenza (H7N3) on 1 farm, and veterinary investigation confirmed influenza subtype H7N3 on the 2 adjacent farms. Surveillance and protection zones were established around all infected premises, and all birds were culled. Persons who had been exposed were offered oseltamivir prophylaxis; those with influenza symptoms were offered oseltamivir treatment and influenza vaccination. All persons at risk were orally instructed to wear personal protective equipment (PPE). DOI: 10.3201/eid1501.07066

show abstract

“…H7 subtype viruses have been isolated from humans in several instances and have been recognized as a pandemic threat for the past decade (3)(4)(5)(6)(7)(8)(9). Clinical symptoms in the vast majority of previously described human H7 influenza cases have been mild; in contrast, many reported human infections with the novel H7N9 influenza virus have been associated with severe disease (1,2,4,6,7,9). Genomic sequence analyses suggest that the novel virus is a triple reassortant of avian strains with the hemagglutinin (HA) derived from a Eurasian H7N3 virus, the neuraminidase from a Eurasian H7N9 or H11N9 virus, and the remaining six segments from a Eurasian H9N2 virus (1,2).…”

mentioning

confidence: 99%

Induction of Cross-Reactive Antibodies to Novel H7N9 Influenza Virus by Recombinant Newcastle Disease Virus Expressing a North American Lineage H7 Subtype Hemagglutinin

Goff

Krammer²,

Hai³

et al. 2013

J Virol

View full text Add to dashboard Cite

Severe human disease caused by the emerging H7N9 influenza virus in China warrants a rapid response. Here, we present a recombinant Newcastle disease virus expressing a North American lineage H7 influenza virus hemagglutinin. Sera from immunized mice were cross-reactive to a broad range of H7 subtype viruses and inhibited hemagglutination by the novel H7 hemagglutinin. Immunized mice were protected against a heterologous H7 subtype challenge, and genetic analysis suggested that cross-protective antibodies recognize conserved antigenic sites.

show abstract

Protective measures and human antibody response during an avian influenza H7N3 outbreak in poultry in British Columbia, Canada

Cited by 55 publications

References 32 publications

Cross-Reactive Anti-Avian H5N1 Influenza Neutralizing Antibodies in a Normal ‘Exposure-Naive’ Australian Blood Donor Population

Cross-Reactive Anti-Avian H5N1 Influenza Neutralizing Antibodies in a Normal ‘Exposure-Naive’ Australian Blood Donor Population

Personal Protective Equipment and Risk for Avian Influenza (H7N3)

Induction of Cross-Reactive Antibodies to Novel H7N9 Influenza Virus by Recombinant Newcastle Disease Virus Expressing a North American Lineage H7 Subtype Hemagglutinin

Contact Info

Product

Resources

About